0001628280-26-034580
SEC filingNet loss narrowed to $8.3M from $9.4M, driven by lower R&D spend, but EPS worsened to -$1.46 due to a reverse stock split, masking underlying progress.
Net loss for Q1 2026 was $8.3 million, a 12.3% improvement from $9.4 million in Q1 2025. The improvement was driven by a decrease in research and development activities, partially offset by an increase in general and administrative expenses. Operating income improved to -$8.7 million from -$9.7 million, reflecting a 9.7% year-over-year improvement. Diluted EPS worsened to -$1.46 from -$0.21 due to a 1-for-8 reverse stock split executed on February 6, 2026, which reduced the share count and amplified the per-share loss.
Revenue remained flat at $212,000 in both Q1 2026 and Q1 2025, entirely derived from a prior collaboration agreement. The company has no approved products and no new revenue-generating partnerships announced during the quarter. This underscores Rallybio's pre-revenue, development-stage status, with all value dependent on the successful advancement of its pipeline, particularly the complement inhibitor RLYB116, a once-weekly subcutaneous C5 inhibitor for complement-related diseases. The lack of revenue growth highlights the binary nature of the investment thesis.
The company executed a 1-for-8 reverse stock split in February 2026, which reduced the number of outstanding shares but did not affect the overall equity value. No other significant changes to the balance sheet were disclosed. The company has no debt or credit facilities, and its capital structure consists solely of common stock and additional paid-in capital.
Management's outlook emphasizes the need for substantial additional capital to fund development of RLYB116 and other programs. The company faces typical biotech risks: clinical trial outcomes, regulatory approval, and competition from other complement inhibitors. The terminated Candid merger, while a distraction, has been resolved, and the associated costs should abate. Investors should monitor R&D spending trends as a proxy for pipeline prioritization and the timing of future capital raises.